TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02567253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive surgery
Description: Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPEC with Cisplatin (75mg/m²)
Description: Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPEC with Cisplatin (100mg/m²)
Description: Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)
Description: Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIPEC with Cisplatin (100mg/m²)
Description: Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
Study: NCT03173794

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CommunityRx-H
Description: CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources.
Study: NCT04707742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betadine© bucal 100 mg/ml
Description: 15 ml 2% povidone-iodine, one minute rinse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oximen® 3%
Description: 15 ml 1% hydrogen peroxide, one minute rinse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clorhexidine Dental PHB©
Description: 15 ml 0,12% clorhexidine, one minute rinse.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitis Xtra Forte©
Description: 15 ml 0,07% cetylpyridinium chloride, one minute rinse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Distilled Water
Description: 15 ml distilled water, one minute rinse.
Study: NCT03540784

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WB-EMS
Description: WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional support
Description: dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional support
Description: dietary monitoring by dietary records; nutritional counselling by dietician, dietary advices: 1.5 g/kg bodyweight/day
Study: NCT01498198

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rotator Cuff Repair Surgery
Description: Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Operative Treatment
Description: Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
Study: NCT00543426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Tablets
Description: Tablet,three times a day,four tablets one time

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: sham Fuzheng Huayu Tablets (placebo)
Description: Tablet, three times a day, four tablets one time
Study: NCT02830776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03% ophthalmic solution
Description: Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
Study: NCT00906087

Intervention type: DRUG
Group type: OTHER
Intervention: Cosopt (combination eyedrop of dorzolamide and timolol)
Description: One drop in each eye every twelve hours for six weeks
Study: NCT01086891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen conserving devices
Description: Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxygen conserving devices
Description: Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
Study: NCT01662674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin and metformin HCl extended release
Description: Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemigliptin/metformin HCl extended release
Description: Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
Study: NCT00440947

Intervention type: DRUG
Group type: OTHER
Intervention: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)
Description: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen

Intervention type: DRUG
Group type: OTHER
Intervention: Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)
Description: Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
Study: NCT00370279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scleral buckling, primary vitrectomy
Description: Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scleral buckling, primary vitrectomy
Description: Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scleral buckling, primary vitrectomy
Description: Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: scleral buckling, primary vitrectomy
Description: Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
Study: NCT01221220

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Packard Pediatric Weight Control Program
Description: Six-month, family-based, group, behavioral weight control program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes
Description: Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
Study: NCT02716987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-831
Description: TAK-831 oral suspension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PGM299
Description: \[18F\]PGM299 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PGM299
Description: \[18F\]PGM299 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PGM299
Description: \[18F\]PGM299 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PGM299
Description: \[18F\]PGM299 injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]PGM299
Description: \[18F\]PGM299 injection
Study: NCT04059172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 200 mg and acetaminphen 650 mg
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 200 mg
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: For morning appliance placement: dose #1 at approximately 9:00 a.m. as appointment starts; dose #2 6 hours later (3:00 p.m- or as soon after school and close to 3 pm as possible.); dose #3 another 6 hours later (9:00 p.m.); dose #4 the following morning upon waking (approximately 24 hours from start and patient will record the time), doses #5 through #7 will be taken every morning upon waking on the second, third, and fourth days, respectively.~For afternoon appliance placement: dose #1 at approximately 2:00 p.m. as appointment starts; dose #2 6 hours later (8:00 p.m.); dose #3 the following morning upon waking (approximately 12 hours later and patient will record the time); dose #4 6 hours later from dose #3 (approximately 24 hours from the initial dose) around 2:00 p.m. (or as soon after school as possible) doses #5 through #7 will be taken every afternoon at 2:00 p.m. on the second, third, and fourth days, respectively.
Study: NCT02681172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuraceq (florbetaben 18F)
Description: Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET
Description: A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
Study: NCT04744207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-248
Description: 120 mg, capsule, once daily for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, once daily for 4 weeks
Study: NCT03580252

Intervention type: OTHER
Intervention: Correlation analyses for the outcomes
Description: No medical intervention would be done. The single arm would receive regular practice of Hammersmith Assessment and MRI / Ultrasound
Study: NCT00573989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Study: NCT01765920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergoferon
Description: 5 ml 3 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 ml 3 times a day
Study: NCT03569579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Tab. 10mg
Description: Memantine Tab. 10mg\* 2T/day, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Tab. 10mg
Description: Memantine Tab. 10mg\* 2T/day, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Tab. 10mg + Donepezil Tab. 10mg
Description: Memantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine Tab. 10mg + Donepezil Tab. 10mg
Description: Memantine Tab. 10mg\* 2T/day + Donepezil Tab. 10mg \* 1T/day, QD, PO
Study: NCT02797340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood draws and urine samples for metformin concentration measurements

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04117243

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: patients will be given 400 microgram misoprostol (2 tablets - Cytotec, Pfizer, G.D. Searle LLC) sublingually immediately before starting skin incision (n=115)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid
Description: patients will be given 1 gm (10 ml) TXA (Kapron, Amoun, Egypt) diluted in 20 ml of Glucose 5% (administered as intravenous infusion over 5 minutes, at least 15 minutes prior to skin incision) (n=115)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: patients will receive an intravenous bolus of 5 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) and 20 IU oxytocin in 500 mL lactated Ringer's solution (infused at a rate of 125 mL/h) following the delivery of the baby (n=115)
Study: NCT01834274

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasiglifam (TAK-875)
Description: Fasiglifam (TAK-875) tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fasiglifam (TAK-875) Placebo
Description: Fasiglifam (TAK-875) placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin Placebo
Description: Sitagliptin placebo-matching tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets
Study: NCT04103684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 30mg per kg per day for 5 days followed by course of oral prednisolone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 0.6mg per kg perday for 5 days
Study: NCT02025907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule taken orally (by mouth) once daily.
Study: NCT00777101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: Tablets 240 mg orally once per day until disease progression or unacceptable toxicity

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lapatinib
Description: Tablets 1250 mg orally once per day until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Tablets 2000 mg/m² given orally in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
Study: NCT02876588

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unrestricted
Description: Users may open up to 4 patient records at a time.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restricted
Description: Users are restricted to open 1 patient record at a time.
Study: NCT04162574

Intervention type: OTHER
Intervention: Recovery Record
Description: Observational data will be obtained through participants entering data on disordered eating episodes, mood, and food in Recovery Record, an app to assist people in managing their eating disorder during the 30 days of the trial. In addition, participants wear an Apple Watch from which passive data (e.g., heart rate, activity, and geolocation) are collected.
Study: NCT02651584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM2038 SC injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL BPN/NX tabs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo SC injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SL placebo tablets
Study: NCT00823355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 1: 100mg / body (1 x 100mg tablet once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 2: 200mg / body (2 x 100mg tablets once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 3: 300mg / body (3 x 100mg tablets once daily)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: forodesine hydrochloride
Description: Cohort 4: 400mg / body (4 x 100mg tablets once daily)
Study: NCT01870427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (2.0 mg)
Description: Intravitreal Aflibercept (2.0 mg)
Study: NCT01265797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial Electrostimulator
Description: participant wears active cranial electrostimulation device for 20 minutes daily for 28 days

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: participant wears sham device for 20 minutes daily for 28 days
Study: NCT02794324

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Voluntary deep-inspiratory breath hold
Description: Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active-breathing-controlled deep-inspiratory breathhold
Description: Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prone treatment
Description: Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-breathing-controlled deep-inspiratory breathhold
Description: The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
Study: NCT04245475

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality psychological pain reduction
Description: attention distraction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality psychological pain reduction
Description: attention distraction
Study: NCT01055600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.